As of 2024-11-13, the EV/EBITDA ratio of BioCryst Pharmaceuticals Inc (BCRX) is -58.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BCRX's latest enterprise value is 2,316.82 mil USD. BCRX's TTM EBITDA according to its financial statements is -39.34 mil USD. Dividing these 2 quantities gives us the above BCRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
Range | Selected | |
Trailing P/E multiples | 15.3x - 18.0x | 16.8x |
Forward P/E multiples | 16.9x - 24.2x | 19.9x |
Fair Price | (6.78) - (6.97) | (7.05) |
Upside | -188.7% - -191.3% | -192.2% |
Date | EV/EBITDA |
2024-10-23 | -61.10 |
2024-10-22 | -60.52 |
2024-10-21 | -58.26 |
2024-10-18 | -58.78 |
2024-10-17 | -58.10 |
2024-10-16 | -58.52 |
2024-10-15 | -58.05 |
2024-10-14 | -57.94 |
2024-10-11 | -57.78 |
2024-10-10 | -56.15 |
2024-10-09 | -56.84 |
2024-10-08 | -56.57 |
2024-10-07 | -57.84 |
2024-10-04 | -58.57 |
2024-10-03 | -57.73 |
2024-10-02 | -57.52 |
2024-10-01 | -57.52 |
2024-09-30 | -58.68 |
2024-09-27 | -58.78 |
2024-09-26 | -58.57 |
2024-09-25 | -58.41 |
2024-09-24 | -58.84 |
2024-09-23 | -59.68 |
2024-09-20 | -61.36 |
2024-09-19 | -61.57 |
2024-09-18 | -60.57 |
2024-09-17 | -60.36 |
2024-09-16 | -60.31 |
2024-09-13 | -60.36 |
2024-09-12 | -59.47 |
2024-09-11 | -59.36 |
2024-09-10 | -59.31 |
2024-09-09 | -59.05 |
2024-09-06 | -60.68 |
2024-09-05 | -61.46 |
2024-09-04 | -62.25 |
2024-09-03 | -62.10 |
2024-08-30 | -64.41 |
2024-08-29 | -64.09 |
2024-08-28 | -63.67 |
2024-08-27 | -61.99 |
2024-08-26 | -61.99 |
2024-08-23 | -61.31 |
2024-08-22 | -60.41 |
2024-08-21 | -60.83 |
2024-08-20 | -59.83 |
2024-08-19 | -60.04 |
2024-08-16 | -58.89 |
2024-08-15 | -58.84 |
2024-08-14 | -60.04 |